Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

Circio Holding

Circio Holding

Circio Holding

2025 Q4 -tulosraportti

Vain PDF

67 päivää sitten

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
26 168--
300--
3 521--
506--
636--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 t sitten
    ·
    1 t sitten
    ·
    If the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
    4 min sitten
    4 min sitten
    Now we are at the point where we are waiting for the results of the tests. The license agreement is coming in August so everyone enjoy the journey and remember to buy exactly as much as you can afford. Remember this date 💯🤝
  • 3 t sitten
    ·
    3 t sitten
    ·
    Now Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
    1 t sitten
    ·
    1 t sitten
    ·
    Yes, I am also super happy about the news. Surely the order book will grow now?
  • 6 t sitten
    ·
    6 t sitten
    ·
    I understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
    1 t sitten
    ·
    1 t sitten
    ·
    Thanks for the answer, so we'll see tomorrow, I find it a bit strange that this isn't the same for everyone, everyone probably bought through Pareto, right?
    1 t sitten
    ·
    1 t sitten
    ·
    Have you checked on vps?
  • 21 t sitten
    ·
    21 t sitten
    ·
    Please continue, so we can have some fun now that it's the weekend
    20 t sitten
    ·
    20 t sitten
    ·
    Imagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
    4 t sitten
    ·
    4 t sitten
    ·
    @119d6c05-f41e-49fb-92f0-26f8f88ba64e Nah, but at least the krone / the economy isn't utterly miserable as in Norway 🤣
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    Nice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅
    28 min sitten
    ·
    28 min sitten
    ·
    Strong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

67 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 t sitten
    ·
    1 t sitten
    ·
    If the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
    4 min sitten
    4 min sitten
    Now we are at the point where we are waiting for the results of the tests. The license agreement is coming in August so everyone enjoy the journey and remember to buy exactly as much as you can afford. Remember this date 💯🤝
  • 3 t sitten
    ·
    3 t sitten
    ·
    Now Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
    1 t sitten
    ·
    1 t sitten
    ·
    Yes, I am also super happy about the news. Surely the order book will grow now?
  • 6 t sitten
    ·
    6 t sitten
    ·
    I understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
    1 t sitten
    ·
    1 t sitten
    ·
    Thanks for the answer, so we'll see tomorrow, I find it a bit strange that this isn't the same for everyone, everyone probably bought through Pareto, right?
    1 t sitten
    ·
    1 t sitten
    ·
    Have you checked on vps?
  • 21 t sitten
    ·
    21 t sitten
    ·
    Please continue, so we can have some fun now that it's the weekend
    20 t sitten
    ·
    20 t sitten
    ·
    Imagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
    4 t sitten
    ·
    4 t sitten
    ·
    @119d6c05-f41e-49fb-92f0-26f8f88ba64e Nah, but at least the krone / the economy isn't utterly miserable as in Norway 🤣
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    Nice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅
    28 min sitten
    ·
    28 min sitten
    ·
    Strong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
26 168--
300--
3 521--
506--
636--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

67 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
  • 1 t sitten
    ·
    1 t sitten
    ·
    If the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
    4 min sitten
    4 min sitten
    Now we are at the point where we are waiting for the results of the tests. The license agreement is coming in August so everyone enjoy the journey and remember to buy exactly as much as you can afford. Remember this date 💯🤝
  • 3 t sitten
    ·
    3 t sitten
    ·
    Now Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
    1 t sitten
    ·
    1 t sitten
    ·
    Yes, I am also super happy about the news. Surely the order book will grow now?
  • 6 t sitten
    ·
    6 t sitten
    ·
    I understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
    1 t sitten
    ·
    1 t sitten
    ·
    Thanks for the answer, so we'll see tomorrow, I find it a bit strange that this isn't the same for everyone, everyone probably bought through Pareto, right?
    1 t sitten
    ·
    1 t sitten
    ·
    Have you checked on vps?
  • 21 t sitten
    ·
    21 t sitten
    ·
    Please continue, so we can have some fun now that it's the weekend
    20 t sitten
    ·
    20 t sitten
    ·
    Imagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
    4 t sitten
    ·
    4 t sitten
    ·
    @119d6c05-f41e-49fb-92f0-26f8f88ba64e Nah, but at least the krone / the economy isn't utterly miserable as in Norway 🤣
  • 1 päivä sitten
    ·
    1 päivä sitten
    ·
    Nice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅
    28 min sitten
    ·
    28 min sitten
    ·
    Strong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
26 168--
300--
3 521--
506--
636--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt